Clinical trials: Colorectal Cancer (CRC)
Colorectal Cancer
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen…
- Trial name
- NCT03035279
- Testing
- SC-006, ABBV-181
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- AbbVie
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Colorectal Cancer
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
There are two parts to this study: (1) an information gathering phase leading to the development of new educational materials; and (2) a study to test the newly developed material.
- Trial name
- NCT01804179
- Testing
- Immunochemical Fecal Occult Blood Test (I-FOBT) Kit, Standard Intervention (SI) Educational Materials, CARES Intervention Educational Materials
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Neoplasms, Anal, Colon, and Rectal Cancers
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed.
- Trial name
- NCT00780988
- Testing
- Autologous tumor cell + CpG vaccine, Autologous hematopoietic and immune cell rescue (transplantation)
- Where
- United States
- Sponsor
- Stanford University
Lynch Syndrome
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
This randomized phase Ib trial studies the side effects and best dose of naproxen in preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in patients with Lynch syndrome.
- Trial name
- NCT02052908
- Testing
- Laboratory Biomarker Analysis, Naproxen
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
- Trial name
- OPTIMISE (NCT04680260)
- Testing
- Standard of care, Circulating tumor DNA guided treatment approach
- Where
- 2 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- Karen-Lise Garm Spindler
Colorectal Cancer
REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis
In colorectal surgery about 30% of postoperative mortality is attributed to anastomotic leak, whit an incidence range between 1.8% and 15.9%.
- Trial name
- ANASTOSEAL (NCT03380858)
- Testing
- colectomy
- Where
- Italy
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute, Naples
Metastatic Colorectal Cancer
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab plus XELOX for 4 cycles followed by maintenance treatment with cetuximab plus capecitabine as first line treatment…
- Trial name
- NCT00531115
- Testing
- cetuximab 5mg/ml
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Cancer, Anal Cancer
Multidimensional Examination of Patients with Colorectal and Anal Cancer
The aim of our cross-sectional research is to assess changes in physical activity, functional capacity, and health status in individuals with colorectal and anal carcinoma using subjective measurement tools, with particular focus…
- Conditions
- Colorectal Cancer, Anal Cancer, Physical Inactivity, Fecal Incontinence
- Trial name
- MECACP (NCT06562140)
- Testing
- No intervention - cross-sectional observational study
- Where
- 2 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- University of Pecs
Lung Cancer, Lung Diseases
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel…
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
- Trial name
- NCT07026110
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Colorectal Cancer, Colorectal Neoplasms
Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry
This study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenoma
- Trial name
- NCT05653960
- Testing
- EMR or ESD
- Where
- Hong Kong
- Volunteers
- 2,500 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Colorectal Cancer
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
RAS mutations are found in nearly half of colorectal cancer patients. However, there is no targeted driver gene drugs have been approved for RAS-mutated patients.
- Trial name
- NCT05634590
- Testing
- Fruquintinib, FOLFIRI, mFOLFOX6
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Hand-Foot Skin Reaction (HFSR)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib…
- Trial name
- ZINCLO-HAND (NCT06856590)
- Testing
- Zinc Supplementation, Clobetasol Propionate 0.05% Cream
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Gazi University
Colorectal Neoplasms Malignant
The COLON Study: Colorectal Cancer Cohort
The main aim of this observational, prospective cohort study is to assess associations of diet and other lifestyle factors with colorectal cancer recurrence, survival and quality of life.
- Trial name
- COLON (NCT03191110)
- Testing
- No intervention: observational study
- Where
- 11 sites in Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Wageningen University
Colon Cancer
Cancer Control Following Polypectomy
This study evaluates strategies for the surveillance of post-polypectomy patients for the control of bladder cancer
- Trial name
- NCT00591279
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
This phase I/II trial studies the best dose and side effects of encorafenib, cetuximab, and nivolumab and how well they work together in treating patients with microsatellite stable, BRAFV600E gene mutated colorectal cancer that…
- Conditions
- BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT04017650
- Testing
- Cetuximab, Encorafenib, Nivolumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005050
- Testing
- ethynyluracil, fluorouracil, oxaliplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Colorectal Cancer
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00538291
- Testing
- cetuximab, capecitabine, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Anal Cancer, Colorectal Cancer
Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
RATIONALE: An anal sphincter prosthesis may replace the need for a permanent colostomy and may improve the quality of life of patients who are undergoing surgery for anal or rectal cancer.
- Conditions
- Anal Cancer, Colorectal Cancer, Perioperative/Postoperative Complications
- Trial name
- NCT00059891
- Testing
- conventional surgery, management of therapy complications
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to detect the extent of locally advanced primary rectal cancer and may also help to measure a patient's response to treatment.
- Trial name
- NCT00004891
- Testing
- chemotherapy, computed tomography, conventional surgery
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center